European committee: Regulators should deny Merck's Lagevrio

A European medical committee recommends rejection of Merck’s COVID-19 treatment, Lagevrio, casting fresh doubt on a pill that also stirs concern among U.S. regulators.A European Medicines Agency committee says marketing authorization for the antiviral pill for use in the European Union should be refused. A statement from the agency says a committee that has been reviewing Merck’s application for more than a year concluded that the drug’s... + full article